Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases

• Main Authors: Viviana Cernigliaro, Rossella Peluso, Beatrice Zedda, Lorenzo Silengo, Emanuela Tolosano, Rinaldo Pellicano, Fiorella Altruda, Sharmila Fagoonee
• Format: Article
• Language: English
• Published: MDPI AG 2020-02-01
• Series: Cells
• Subjects: liver diseases; transplantation; cell therapy; extracellular vesicles; organoids; scaffolds; organ printing
• Online Access: https://www.mdpi.com/2073-4409/9/2/386

Liver diseases represent a major global health issue, and currently, liver transplantation is the only viable alternative to reduce mortality rates in patients with end-stage liver diseases. However, scarcity of donor organs and risk of recidivism requiring a re-transplantation remain major obstacles. Hence, much hope has turned towards cell-based therapy. Hepatocyte-like cells obtained from embryonic stem cells or adult stem cells bearing multipotent or pluripotent characteristics, as well as cell-based systems, such as organoids, bio-artificial liver devices, bioscaffolds and organ printing are indeed promising. New approaches based on extracellular vesicles are also being investigated as cell substitutes. Extracellular vesicles, through the transfer of bioactive molecules, can modulate liver regeneration and restore hepatic function. This review provides an update on the current state-of-art cell-based and cell-free strategies as alternatives to liver transplantation for patients with end-stage liver diseases.